Revision as of 17:17, 5 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEMBL_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|← Previous edit | Revision as of 09:18, 8 August 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|erroNext edit → | ||
Line 1: | Line 1: | ||
{{drugbox | {{drugbox | ||
⚫ | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| Verifiedfields = changed | |||
⚫ | | UNII_Ref = {{fdacite| |
||
| UNII = 2Y065P7MYR | | UNII = 2Y065P7MYR | ||
| verifiedrevid = |
| verifiedrevid = 443210436 | ||
|IUPAC_name = 5,6-bis(4-methoxyphenyl)-3-methyl-1,2,4-triazine | |IUPAC_name = 5,6-bis(4-methoxyphenyl)-3-methyl-1,2,4-triazine | ||
| image=Anitrazafen structure.png | | image=Anitrazafen structure.png | ||
Line 21: | Line 20: | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| ChemSpiderID=40409 | | ChemSpiderID=40409 | ||
| KEGG_Ref = {{keggcite| |
| KEGG_Ref = {{keggcite|correct|kegg}} | ||
| KEGG = D02948 | | KEGG = D02948 | ||
| C=18 | H=17 | N=3 | O=2 | | C=18 | H=17 | N=3 | O=2 |
Revision as of 09:18, 8 August 2011
Pharmaceutical compoundIdentifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H17N3O2 |
Molar mass | 307.35 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Anitrazifen is a drug displaying COX-2 inhibitor activity. See also for celebrex.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
---|---|
pyrazolones / pyrazolidines | |
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
---|---|
pyrazolones / pyrazolidines | |
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |